Maxine Bauzon

905 total citations
25 papers, 606 citations indexed

About

Maxine Bauzon is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Maxine Bauzon has authored 25 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Genetics and 10 papers in Molecular Biology. Recurrent topics in Maxine Bauzon's work include Virus-based gene therapy research (11 papers), CAR-T cell therapy research (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (5 papers). Maxine Bauzon is often cited by papers focused on Virus-based gene therapy research (11 papers), CAR-T cell therapy research (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (5 papers). Maxine Bauzon collaborates with scholars based in United States, Germany and United Kingdom. Maxine Bauzon's co-authors include Terry Hermiston, Leonard W. Seymour, André Lieber, Robyn M. Barfield, Irene Kuhn, Penelope M. Drake, Richard N. Harkins, David Rabuka, Gabor M. Rubanyi and Bin Shen and has published in prestigious journals such as Blood, PLoS ONE and The FASEB Journal.

In The Last Decade

Maxine Bauzon

24 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maxine Bauzon United States 12 397 361 303 89 77 25 606
Conrado Soria United States 8 519 1.3× 476 1.3× 558 1.8× 126 1.4× 100 1.3× 8 913
Yvette Stallwood United Kingdom 7 277 0.7× 146 0.4× 413 1.4× 43 0.5× 92 1.2× 8 543
Klaus Mantwill Germany 15 341 0.9× 301 0.8× 405 1.3× 83 0.9× 76 1.0× 25 631
Carlos Alberto Fajardo Spain 13 475 1.2× 720 2.0× 395 1.3× 95 1.1× 335 4.4× 16 980
Jacqueline Kintz France 11 429 1.1× 252 0.7× 331 1.1× 104 1.2× 118 1.5× 11 618
Assia L. Angelova Germany 14 582 1.5× 440 1.2× 250 0.8× 104 1.2× 115 1.5× 34 733
Gerd Maass Austria 9 200 0.5× 285 0.8× 289 1.0× 47 0.5× 268 3.5× 12 657
A.G. Jochemsen Netherlands 15 272 0.7× 356 1.0× 683 2.3× 85 1.0× 63 0.8× 20 863
S. W. Lowe United States 2 238 0.6× 382 1.1× 493 1.6× 135 1.5× 69 0.9× 3 677
Amanda Rosewell Shaw United States 14 722 1.8× 761 2.1× 473 1.6× 123 1.4× 260 3.4× 24 1.0k

Countries citing papers authored by Maxine Bauzon

Since Specialization
Citations

This map shows the geographic impact of Maxine Bauzon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxine Bauzon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxine Bauzon more than expected).

Fields of papers citing papers by Maxine Bauzon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxine Bauzon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxine Bauzon. The network helps show where Maxine Bauzon may publish in the future.

Co-authorship network of co-authors of Maxine Bauzon

This figure shows the co-authorship network connecting the top 25 collaborators of Maxine Bauzon. A scholar is included among the top collaborators of Maxine Bauzon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxine Bauzon. Maxine Bauzon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mendelsohn, Brian A., Kathleen R. Gogas, Jeffrey N. Higaki, et al.. (2025). Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4. Molecular Cancer Therapeutics. 24(12). 1856–1866. 1 indexed citations
2.
Fernández, José A., et al.. (2023). Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library. Blood Advances. 7(13). 3036–3048. 3 indexed citations
3.
Perez, Gloria I., et al.. (2023). Phosphatidylserine-Exposing Annexin A1-Positive Extracellular Vesicles: Potential Cancer Biomarkers. Vaccines. 11(3). 639–639. 20 indexed citations
4.
Hardy, Jonathan, Maxine Bauzon, Ashley V. Makela, et al.. (2023). Gla‐domain mediated targeting of externalized phosphatidylserine for intracellular delivery. The FASEB Journal. 37(8). e23113–e23113. 5 indexed citations
5.
6.
Sim, Derek, et al.. (2021). In vitro characterization of CT‐001—a short‐acting factor VIIa with enhanced prohemostatic activity. Research and Practice in Thrombosis and Haemostasis. 5(5). e12530–e12530. 3 indexed citations
7.
Chuprakov, Stepan, Robyn M. Barfield, Maxine Bauzon, et al.. (2021). Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates. Bioconjugate Chemistry. 32(4). 746–754. 49 indexed citations
8.
Barfield, Robyn M., Yun Cheol Kim, Stepan Chuprakov, et al.. (2020). A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. Molecular Cancer Therapeutics. 19(9). 1866–1874. 11 indexed citations
9.
Alt, Carsten, Shujun Yuan, Faye Wu, et al.. (2019). Long-Acting IL-33 Mobilizes High-Quality Hematopoietic Stem and Progenitor Cells More Efficiently Than Granulocyte Colony-Stimulating Factor or AMD3100. Biology of Blood and Marrow Transplantation. 25(8). 1475–1485. 5 indexed citations
10.
Bauzon, Maxine, et al.. (2019). Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. OncoImmunology. 8(4). e1565859–e1565859. 46 indexed citations
11.
12.
Di, Ying, Maxine Bauzon, Janet Lei-Rossmann, et al.. (2017). Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 5. 62–74. 40 indexed citations
13.
Kuhn, Irene, Maxine Bauzon, Nicola Green, et al.. (2016). OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Molecular Therapy — Oncolytics. 4. 55–66. 17 indexed citations
14.
Bauzon, Maxine & Terry Hermiston. (2014). Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy. Frontiers in Immunology. 5. 74–74. 38 indexed citations
15.
Bauzon, Maxine, Faguang Jin, Peter J. Kretschmer, & Terry Hermiston. (2009). In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer. Gene Therapy. 16(9). 1169–1174. 9 indexed citations
16.
Bauzon, Maxine & Terry Hermiston. (2008). Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.. PubMed. 10(4). 350–5. 7 indexed citations
17.
Kuhn, Irene, Paul Harden, Maxine Bauzon, et al.. (2008). Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE. 3(6). e2409–e2409. 153 indexed citations
18.
Shen, Bin, Maxine Bauzon, & Terry Hermiston. (2006). The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Therapy. 13(12). 986–990. 36 indexed citations
19.
Petry, Harald, Linda Cashion, Paul Szymanski, et al.. (2006). Mx1 and IP-10: Biomarkers to Measure IFN- β Activity in Mice Following Gene-Based Delivery. Journal of Interferon & Cytokine Research. 26(10). 699–705. 16 indexed citations
20.
Johnson, Leisa, et al.. (2001). Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Therapy. 8(15). 1123–1131. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Conrado Soria Breakdown of academic impact, for papers by Yvette Stallwood Breakdown of academic impact, for papers by Klaus Mantwill Breakdown of academic impact, for papers by Carlos Alberto Fajardo Breakdown of academic impact, for papers by Jacqueline Kintz Breakdown of academic impact, for papers by Assia L. Angelova Breakdown of academic impact, for papers by Gerd Maass Breakdown of academic impact, for papers by A.G. Jochemsen Breakdown of academic impact, for papers by S. W. Lowe Breakdown of academic impact, for papers by Amanda Rosewell Shaw
Rankless by CCL
2026